Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Nymox Pharmaceutical Corporation (NYMXF) had Normalized Pre-Tax Income of $-4.49M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-4.49M |
|
-- |
|
-- |
|
$4.28M |
|
$-4.28M |
|
$-0.21M |
|
$-4.49M |
|
|
Normalized Pre-Tax Income |
$-4.49M |
$-4.49M |
|
$-4.49M |
|
$-4.49M |
|
$-4.49M |
|
$-4.28M |
|
$-4.28M |
|
93.67M |
|
93.67M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$0.65M |
|
$0.00M |
|
$0.00M |
|
$0.65M |
|
$7.43M |
|
-- |
|
-- |
|
$7.43M |
|
$-6.78M |
|
$-6.78M |
|
$-6.78M |
|
93.54M |
|
| Cash Flow Statement Financials | |
$-2.60M |
|
-- |
|
$2.60M |
|
$0.07M |
|
$0.07M |
|
$0.00M |
|
$0.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
66.30% |
|
66.30% |
|
-686.85% |
|
66.30% |
|
$-0.07 |
|
$-0.03 |
|
$-0.03 |
|